Prime

Our new mantra: Dedication, tenacity, empathy. Genuine passion, real courage and mutual respect. Take a stand, fight a corner, be the change, make the difference. And support each other, always. Because together we accelerate life-changing solutions. #oneprime #acceleratingprogress

The countdown is on ⏳ Mark your calendars - the announcement date is almost here! We’re excited to share how we’re shaping the future of healthcare communications. By addressing the everyday challenges our clients face, we’re unlocking new possibilities and strengthening our partnerships. The clock is ticking, and we can’t wait for you to see what’s coming. Are you ready? ⏳ Only 2 more days until the announcement. 🌟 Wednesday, 6th November—don’t miss it! #FutureOfHealthcare #HealthcareInnovation #Pharmaceuticals #Innovation

Happy Halloween from the Prime team 🎃 Yesterday we celebrated in the office together with some Halloween treats and drinks. Check out the highlights from our Halloween festivities! 🕷️👻 #halloween #workplace #team

Something is coming... For 26 years, Prime has been at the forefront of healthcare communications, delivering innovative strategies and scientific expertise to improve patient outcomes worldwide 🌎 Healthcare is evolving, and so are the challenges. That’s why we’ve designed an agency built around solving them. We’re agile, innovative, and ready to tackle these issues head-on with solutions tailored to individual client needs. Stay tuned to find out more 👀 #FutureOfHealthcare #HealthcareInnovation #Pharmaceuticals #Innovation 

The Prime team had a full house yesterday at our panel on demonstrating value in rare diseases at the World Orphan Drug Congress Europe 2024! Thank you to our expert panel and everyone who joined us! It has been a busy few days engaging with both new and long-standing clients, collaborating on innovative solutions to bring life-changing treatments to patients. Stay tuned - there's more on the way for day 3! #WorldOrphanDrugCongress #WODC #RareDiseases #OrphanDrugs #MarketAccess #HealthEconomics

Sue O'Leary Executive Vice President, Evidence & Access, Prime will be moderating a panel discussion tomorrow on ‘Optimising Value Demonstration and Evidence in Rare Disease’!    🗓️ Date: Thursday, 24th October 🕒 Time: 11:55 AM 📍 Location: Theatre 6, WODC Please join her alongside industry expert panelists Stuart Mealing, Jennifer Quinn, Mukesh Sharma, PhD and Simon S. for a deep dive into this critical topic. This session will explore how access bodies like NICE assess rare disease evidence during health technology assessments. The discussion will also delve into innovative methods beyond clinical trials that pharma companies can leverage to demonstrate product value. Additionally, we will discuss how pharmaceutical companies can internally organize their processes to ensure efficient and effective evidence planning while adapting to changing roles and responsibilities. We’re looking forward to an insightful discussion! #WODC #RareDiseases #ValueDemonstration #RealWorldEvidence #PanelDiscussion

Prime has arrived at the World Orphan Drug Congress Europe 2024 in Barcelona! 🎉 We’re excited to dive into insightful discussions on strategy, advocacy, and partnerships for the orphan drug industry, with the goal of driving impactful change in the rare disease space. Looking forward to networking with industry peers and discovering ways to advance care and treatment for rare disease communities. Let’s shape the future together! Please visit us at booth 61! For more information on our services please visit www.primeglobalpeople.com #WODC #RareDiseases #OrphanDrugs #HealthcareInnovation #Networking #Prime #Impact

Meet with Prime’s expert integrated strategy team to explore optimising evidence for your rare disease assets! At Prime we understand the importance of ensuring that the right evidence is captured early in development to drive investment and secure patient access through the multiple payer assessment bodies. As patient-focused outcomes and analytics is key in rare disease, it is essential that teams break down silos and are strategically aligned across functions, starting in early development. Our integrated team of leaders Peter, Tom and Sue bring together their expertise in strategic planning, outcomes analytics and market access and look forward to discussing your challenges at WODC. Please visit us at booth 61 or contact Sue O'Leary, Peter Agathangelou or Tom Burke on the WODC app! #WODC #RareDiseases #OrphanDrugs #HealthcareInnovation #Networking #Prime #Impact

Join us for an insightful panel discussion at the World Orphan Drug Congress Europe 2024 in Barcelona! Sue O'Leary, Executive Vice President, Evidence & Access, Prime will be moderating the discussion on ‘Optimising Value Demonstration and Evidence in Rare Disease’.    🗓️ Date: Thursday, 24th October 🕒 Time: 11:55 AM 📍 Location: Theatre 6, WODC This session will explore how access bodies like NICE assess rare disease evidence during health technology assessments. The discussion will also delve into innovative methods beyond clinical trials that pharma companies can leverage to demonstrate product value. Additionally, we will discuss how pharmaceutical companies can internally organize their processes to ensure efficient and effective evidence planning while adapting to changing roles and responsibilities. Meet Our Esteemed Panelists: Sue O'Leary - Moderator, Executive Vice President, Evidence & Access, Prime Jennifer Quinn, Head of Global Value and Access, Debiopharm International Stuart Mealing, Associate Director (HEOR), York Health Economics Consortium & NICE HST Committee Member Simon S.,(Simon Shohet) PhD, Vice President, International Market Access and HEOR, Amicus Therapeutics Mukesh Sharma, PhD, Head of Early Pipeline and Business Development, Alexion Pharmaceuticals Don’t miss this opportunity to gain valuable insights and network with industry leaders in the rare disease space. We look forward to seeing you there! #RareDisease #Pharma #ValueDemonstration #WODC2024

Wishing you a meaningful Yom Kippur! #YomKippur